Real-world treatment and outcomes of frontline chemotherapy in patients with metastatic pancreatic cancer.

e16249Background: The difference between the FOLFIRINOX and gemcitabine/nab-paclitaxel (GnP) regimens’ clinical trial designs limit the ability to generate cross-study comparisons. Therefore, there...